Tonix Pharmaceuticals (NASDAQ:TNXP) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report issued on Monday morning. The brokerage issued a sell rating on the stock.

Separately, Alliance Global Partners raised their price target on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Trading Down 8.1 %

Shares of Tonix Pharmaceuticals stock opened at $0.15 on Monday. The business has a 50 day moving average price of $0.18 and a 200 day moving average price of $1.84. The company has a market capitalization of $21.19 million, a P/E ratio of 0.00 and a beta of 2.08. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. Tonix Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings results on Friday, August 16th. The company reported ($19.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($9.91) by ($9.37). The company had revenue of $2.21 million during the quarter, compared to analyst estimates of $3.50 million. Tonix Pharmaceuticals had a negative return on equity of 158.27% and a negative net margin of 1,196.11%. Sell-side analysts anticipate that Tonix Pharmaceuticals will post -18 EPS for the current fiscal year.

Hedge Funds Weigh In On Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 335,373 shares of the company’s stock after purchasing an additional 242,358 shares during the period. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. Institutional investors own 82.26% of the company’s stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.